IBA 53.45    Updated: 04-28-2017 $IBA Last Trade:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
21
IBA 53.45    Updated: 04-28-2017 $IBA
Last Trade: 4/28/2017 4:02:00 PM
Last 53.45   
Open 53.47
Previous Close 53.45
Day High / Low 54.81 / 52.75
Year High / Low 56.10 / 45.32
Volume 36,154
Projected Volume 36154 (187%)
# of Trades / Projected 236 / 236
Dividend / Yield 0.83 / 1.55%
Abnormal Activity ABNORMAL DAY UP
Abnormal Volume NO
Gap GAP UP
Candle BEARISH
Volatility Today MEDIUM
Volatility Yesterday MEDIUM
Price Relativity
From 40 Day High 97%
From 80 Day High 97%
From 150 Day High 97%
From 40 Day Low 111%
From 80 Day Low 116%
From 150 Day Low 117%
Pivot Analysis
Price Pivot $ 53.67
Day Resistance 1 $ 54.59
Day Support 1 $ 52.53
Day Resistance 2 $ 55.73
Day Support 2 $ 51.61
Consolidations
Short Term NO
Medium Term YES
Long Term YES
Volume Indicators
20 Day Avg Vol 19,333
Today / 20 Day Avg Vol ABOVE
150 Day Avg Vol 24,147
Today / 150 Day Avg Vol ABOVE
Abnormal Volume NO
William Volume Accumulation bearish
Volume Price Trend bearish
Momentum Indicators
10 Day Trend bearish
40 Day Trend bullish
100 Day Trend bullish
Stochastics bearish
RSI bearish
MACD bullish
Moving Average Indictors
15 Day Trend bearish
45 Day Trend bullish
100 Day Trend bullish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? ABNORMAL DAY UP
Volatility Index Today MEDIUM
Volatility Index Yesterday MEDIUM
10 Day Volatility INCREASING
20 Day Volatility DECREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Revolutionary AI Improves Immunology and Cancer Research Efficiency

Updated Category News Views 107

Transforming Research with AI Technology BD (Becton, Dickinson and Company) (NYSE: BDX) has recently launched an innovative tool that is set to transform the landscape of immunology and cancer research. The introduction of the BD® Research Cloud 7.0, featuring the BD Horizon™ Panel Maker, is redefining how scientists approach experimental design in these critical...

Continue Reading
Strategic Collaboration of IONETIX and AlfaRim Medical Unveiled

Updated Category News Views 347

Strategic Partnership Between IONETIX and AlfaRim Medical In a significant move within the medical isotope industry, IONETIX Corporation has announced a strategic partnership with AlfaRim Medical B.V. This collaboration sets the stage for accelerating the commercial production of Actinium-225, a crucial isotope used in targeted alpha therapies for various cancers. As...

Continue Reading
Endeavour Silver's Terronera Project Achieves Major Milestones

Updated Category News Views 62

Endeavour Silver's Terronera Project Update: Key Developments Endeavour Silver Corp. (NYSE: EXK; TSX: EDR) has unveiled a significant third-quarter construction progress report for its Terronera Project located in Mexico. The company takes pride in its remarkable strides toward achieving full operational readiness. Progress Overview The Terronera Project has progressed...

Continue Reading
Healthcare Sector Faces Major Cybersecurity Challenges Amid Breaches

Updated Category News Views 224

Significant Rise in Healthcare Data Breaches In the healthcare industry, data breaches hit a dramatic peak, leading to an alarming tally of over 276 million records compromised. This stunning figure represents a staggering 64.1% increase from prior years, illustrating profound vulnerabilities in the protection of sensitive patient information. As such, the harsh reality...

Continue Reading
Tempus AI Investors Prepare for Class Action Opportunity

Updated Category News Views 131

Understanding the Tempus AI Class Action Lawsuit Investors in Tempus AI, Inc. (NASDAQ: TEM) may find themselves in a position to lead a class action lawsuit following substantial financial losses. This legal opportunity arises from significant allegations against the company, which purports to be advancing precision medicine through artificial intelligence. Who Can...

Continue Reading